Neumora Therapeutics, Inc.
NMRA
$1.63
$0.010.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.47% | 10.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.82% | 12.74% | |||
| Operating Income | 23.82% | -12.74% | |||
| Income Before Tax | 22.36% | -15.42% | |||
| Income Tax Expenses | -76.19% | -- | |||
| Earnings from Continuing Operations | 22.45% | -15.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.45% | -15.60% | |||
| EBIT | 23.82% | -12.74% | |||
| EBITDA | 23.68% | -12.77% | |||
| EPS Basic | 22.56% | -15.24% | |||
| Normalized Basic EPS | 22.49% | -15.06% | |||
| EPS Diluted | 22.56% | -15.24% | |||
| Normalized Diluted EPS | 22.49% | -15.06% | |||
| Average Basic Shares Outstanding | 0.15% | 0.29% | |||
| Average Diluted Shares Outstanding | 0.15% | 0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||